Shots:
- Boston Scientific has entered into a definitive agreement to acquire Nalu Medical, expanding its neuromodulation portfolio for chronic pain with the Nalu Neurostimulation System
- As per the deal, Boston Scientific will acquire the remaining equity of Nalu Medical for ~$533M in cash, in which it has been a strategic investor since 2017; closing expected in H1’26
- Nalu System, an FDA-cleared device, provides targeted relief for adults with chronic peripheral nerve pain using a miniaturized, battery-free implant that delivers mild electrical impulses powered wirelessly, interrupting pain signals before they reach the brain
Ref: Boston Scientific | Image: Nalu Medical | Press Release
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
